Jim Cramer Names His Best Picks for Cancer Cures (BMY, IMGN, PFE, DNDN, EXEL)

Cancer is one of the most devastating diseases in the planet. Cancer has killed over half a million American and it continues to grow. In fact, almost everyone knows a family member, a friend or a member of the community that has been touched by this disease.

CNBC,com’s Jim Cramer reveals his Picks for the best companies that are working on Cancer Cures and Treatments. In that list, you can find Bristol Myers Squibb (NYSE: BMY) . The smart acquisition strategy of Bristol Myers Squibb has brought in seven more companies since 2000. One company is Medarex which is working on a drug for the treatment of Metastic Melanoma. Currently, the drug is in its third stage of development. BMY shares went up 1.81% to 23.05 in today’s trading.

Pfizer (NYSE: PFE), another of Cramer’s Picks, offers one of the most diversified list of drugs among health care companies and the acquisition of Wyeth can only help increase its income from cancer treatment drugs. Currently, Pfizer has 22 cancer drugs including Aromasin, used for Breast Cancer treatment; Sutent, a drug that limits blood into tumors; and Campotar, a drug used to treat colon cancer. Pfizer rose to 2.77% to 17.43.

Another one of Cramer's Picks is Immunogen (NASDAQ: IMGN). Immunogen used to be one of the highest priced stocks in Nasdaq in year 2000 but soon fell because of clinical trials that had less than favorable result. Now, Cramer believes that Immunogen is set to rebound behind the breast cancer drug T-DM1. T-DM1 is currently in Phase II of clinical trials and is set to replace the industry standard Herceptin. The results of the clinical trials will be released on Dec. 12.

The next company on Cramer’s list is Dendreon (NASDAQ: DNDN) which is an acquisition target for Bristol Myer Squibb or Merck. The interest on this company is fueled by the drug Provenge, which is in the late stages of development and estimated to be released to the commercial market by the middle of 2010. Sales for Provenge is expected to reach $730 million by 2011 and $4 billion by 2020. Shares for Dendreon were up 2.45% to $29.31.

On his final play, Cramer picked Exelixis (NASDAQ EXEL) because of their drug XL184, a drug designed to stop tumor growth. Exelixis is currently working with large partners in the development of XL184 and these companies include Bristol Myers Squibb, Roche (NASDAQ: RHHBY), and Sanofi Aventis (NYSE: SNY). Cramer picks EXEL as a highly speculative stock and its success is dependent on the success of XL184 and its potential in the Merger and Acquisition market as larger companies tend to buy out their smaller partners.

For the complete list of Cramer’s Picks for Cancer Cures you can go to this link:
http://www.cnbc.com/id/33728388/?slide=1